Document 2806
 DOCN  M94A2806
 TI    Equimmune in treatment of HIV infected patients.
 DT    9412
 AU    Bissbort SH; Davis H; van Brummelen R; Miller S
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):220 (abstract no. PB0309). Unique
       Identifier : AIDSLINE ICA10/94369769
 AB    OBJECTIVE: The main objective was to test Equimmune; a recently
       formulated immunostimulant, in HIV infected and AIDS patients. METHODS:
       An open, multi-center, prospective, clinical trial with 103 patients
       with laboratory confirmed HIV positivity and a CD4 count at entry lower
       than 650/ml was done. The patients were evaluated at four-weekly
       intervals over a 6 month period. The four main variables recorded were
       CD4 count, CD4%, S-b2-Microglobulin and Karnofsky score. The change in
       variable over time was evaluated statistically by means of the Sign test
       and the Wilcoxon Signed Ranks test. RESULTS: A rise in CD4 count (p <
       0.0001), as well as in CD4% (p < 0.0001) were observed after already 3
       months, this proved to be highly significant. There was an associated
       improvement in the Karnofsky score (p < 0.0001), with a significant
       decrease in the S-b2-Microglobulin levels (p < 0.0026). No major side
       effects were reported. CONCLUSION: Equimmune seems to have a definite
       beneficial effect for the HIV infected patient as an immunostimulant.
 DE    beta 2-Microglobulin/ANALYSIS  Acquired Immunodeficiency
       Syndrome/THERAPY  Adjuvants, Immunologic/*THERAPEUTIC USE  Human  HIV
       Infections/*THERAPY  Karnofsky Performance Status  Leukocyte Count
       Treatment Outcome  T4 Lymphocytes  CLINICAL TRIAL  MEETING ABSTRACT
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).